Resectable Oropharyngeal Squamous Cell Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-02-14
Clinical Trial Update: NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery [Phase 1]
A Phase 1 trial of NT-I7 for recurrent squamous cell carcinoma of the head and neck undergoing surgery was terminated.
CLINICAL_TRIALS research · 2024-12-11
Clinical Trial Update: Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma [Phase 2]
A Phase 2 clinical trial is planned to evaluate preoperative tislelizumab with cetuximab and chemotherapy followed by salvage surgery, plus …